Lexicon leaps as FDA approves Inpefa for HF

The US Food and Drug Administration (FDA) on Friday approved Inpefa (sotagliflozin), developed by Lexicon Pharmaceuticals (Nasdaq: LXRX), whose shares closed up almost 10% and leapt a further 17.3% to $3.73 in after-hours trading.

Inpefa is a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

The broad label encompasses heart failure patients across the full range of left ventricular ejection fraction (LVEF), including preserved ejection fraction and reduced ejection fraction, and for patients with or without diabetes, the Texas, USA-based company said.